• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.

作者信息

Maack Christoph, Lehrke Michael, Backs Johannes, Heinzel Frank R, Hulot Jean-Sebastien, Marx Nikolaus, Paulus Walter J, Rossignol Patrick, Taegtmeyer Heinrich, Bauersachs Johann, Bayes-Genis Antoni, Brutsaert Dirk, Bugger Heiko, Clarke Kieran, Cosentino Francesco, De Keulenaer Gilles, Dei Cas Alessandra, González Arantxa, Huelsmann Martin, Iaccarino Guido, Lunde Ida Gjervold, Lyon Alexander R, Pollesello Piero, Rena Graham, Riksen Niels P, Rosano Giuseppe, Staels Bart, van Laake Linda W, Wanner Christoph, Farmakis Dimitrios, Filippatos Gerasimos, Ruschitzka Frank, Seferovic Petar, de Boer Rudolf A, Heymans Stephane

机构信息

Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany.

Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany.

出版信息

Eur Heart J. 2018 Dec 21;39(48):4243-4254. doi: 10.1093/eurheartj/ehy596.

DOI:10.1093/eurheartj/ehy596
PMID:30295797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6302261/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/ddcfa07c8abd/ehy596f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/82d3a4a5aee7/ehy596f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/78c785aac3e6/ehy596f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/a17d43f1354e/ehy596f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/9fbeb40c8225/ehy596f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/ddcfa07c8abd/ehy596f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/82d3a4a5aee7/ehy596f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/78c785aac3e6/ehy596f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/a17d43f1354e/ehy596f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/9fbeb40c8225/ehy596f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9f/6302261/ddcfa07c8abd/ehy596f5.jpg

相似文献

1
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.心力衰竭与糖尿病：代谢改变及治疗干预——心力衰竭协会-欧洲心脏病学会转化研究委员会的最新综述
Eur Heart J. 2018 Dec 21;39(48):4243-4254. doi: 10.1093/eurheartj/ehy596.
2
Meeting highlights from the 2013 European Society of Cardiology Heart Failure Association Winter Meeting on Translational Heart Failure Research.2013年欧洲心脏病学会心力衰竭协会关于转化性心力衰竭研究的冬季会议亮点。
Eur J Heart Fail. 2014 Jan;16(1):6-14. doi: 10.1002/ejhf.10. Epub 2013 Dec 14.
3
The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.自主神经系统作为心力衰竭的治疗靶点：欧洲心脏病学会心力衰竭协会转化研究委员会的科学立场声明。
Eur J Heart Fail. 2017 Nov;19(11):1361-1378. doi: 10.1002/ejhf.921. Epub 2017 Sep 26.
4
Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease.患有心力衰竭、糖尿病和慢性肾脏病的医疗保险受益人的降糖药物使用情况
Circ Heart Fail. 2016 Jul;9(7). doi: 10.1161/CIRCHEARTFAILURE.115.002638.
5
Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.磺脲类药物与二甲双胍单药治疗对心力衰竭风险的比较安全性：一项队列研究。
J Am Heart Assoc. 2017 Apr 19;6(4):e005379. doi: 10.1161/JAHA.116.005379.
6
Controlling diabetes with diet and oral hypoglycemic agents.通过饮食和口服降糖药控制糖尿病。
Geriatrics. 1976 Oct;31(10):67-70.
7
[Long term efficacy and tolerance of antidiabetic treatments. New data].[抗糖尿病治疗的长期疗效和耐受性。新数据]
Nouv Presse Med. 1974 Jun 15;3(24):1551-4.
8
[Treatment of diabetes mellitus with glibornurid].用格列波脲治疗糖尿病
Minerva Med. 1973 Oct 24;64(75):3900-6.
9
[Glipizide, a new sulfonylurea in the treatment of diabetes mellitus].格列吡嗪，一种治疗糖尿病的新型磺脲类药物
Prensa Med Mex. 1973 May-Jun;38(5):211-4.
10
[Therapeutic trial of a new antidiabetic with vascular action: 1702 SE].[一种具有血管作用的新型抗糖尿病药物的治疗试验：1702 SE]
Lille Med. 1972 Oct;17(9):Suppl 6:1332-6.

引用本文的文献

1
Renal Biomarkers and Prognosis in HFpEF and HFrEF: The Role of Albuminuria and eGFR-A Systematic Review.射血分数保留的心力衰竭和射血分数降低的心力衰竭中的肾脏生物标志物与预后：蛋白尿和估算肾小球滤过率的作用——一项系统评价
Medicina (Kaunas). 2025 Jul 30;61(8):1386. doi: 10.3390/medicina61081386.
2
Established and Emerging Roles of Epigenetic Regulation in Diabetic Cardiomyopathy.表观遗传调控在糖尿病心肌病中的既定作用与新出现的作用
Diabetes Metab Res Rev. 2025 Sep;41(6):e70081. doi: 10.1002/dmrr.70081.
3
Deep phenotyping of a modified diabetic cardiomyopathy mouse model which reflects clinical disease progression.

本文引用的文献

1
Metabolic remodelling in heart failure.心力衰竭中的代谢重编程。
Nat Rev Cardiol. 2018 Aug;15(8):457-470. doi: 10.1038/s41569-018-0044-6.
2
Mitochondrial uncoupling, ROS generation and cardioprotection.线粒体解偶联、ROS 生成与心脏保护。
Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):940-950. doi: 10.1016/j.bbabio.2018.05.019. Epub 2018 May 31.
3
Calcium Signaling and Reactive Oxygen Species in Mitochondria.钙信号与线粒体中的活性氧物种。
一种反映临床疾病进展的改良糖尿病性心肌病小鼠模型的深度表型分析。
Diabetol Metab Syndr. 2025 Aug 14;17(1):334. doi: 10.1186/s13098-025-01913-3.
4
The mitochondrial hub gene UCHL1 May serve as a potential biomarker for diagnosing diabetic cardiomyopathy: a comprehensive integration of biological pathways.线粒体枢纽基因UCHL1可能作为诊断糖尿病性心肌病的潜在生物标志物：生物途径的综合整合
BMC Med Genomics. 2025 Aug 11;18(1):129. doi: 10.1186/s12920-025-02199-0.
5
Mechano-energetic uncoupling in heart failure.心力衰竭中的机械-能量解偶联
Nat Rev Cardiol. 2025 Jun 22. doi: 10.1038/s41569-025-01167-6.
6
The impact of diabetes duration and glycemic control on ejection fraction in heart failure patients.糖尿病病程和血糖控制对心力衰竭患者射血分数的影响。
Acta Diabetol. 2025 May 7. doi: 10.1007/s00592-025-02519-x.
7
Heart Rate Variability, Microvascular Dysfunction, and Inflammation: Exploring the Potential of taVNS in Managing Heart Failure in Type 2 Diabetes Mellitus.心率变异性、微血管功能障碍与炎症：探索经皮耳迷走神经刺激疗法（taVNS）在2型糖尿病性心力衰竭管理中的潜力
Biomolecules. 2025 Mar 29;15(4):499. doi: 10.3390/biom15040499.
8
Association of cardiovascular-kidney-metabolic syndrome with all-cause and cardiovascular mortality: A prospective cohort study.心血管-肾脏-代谢综合征与全因死亡率和心血管死亡率的关联：一项前瞻性队列研究。
Am J Prev Cardiol. 2025 Mar 29;22:100985. doi: 10.1016/j.ajpc.2025.100985. eCollection 2025 Jun.
9
Estimated glucose disposal rate outperforms other insulin resistance surrogates in predicting incident cardiovascular diseases in cardiovascular-kidney-metabolic syndrome stages 0-3 and the development of a machine learning prediction model: a nationwide prospective cohort study.在预测心血管-肾脏-代谢综合征0-3期的心血管疾病发病及构建机器学习预测模型方面，估计的葡萄糖处置率优于其他胰岛素抵抗替代指标：一项全国性前瞻性队列研究。
Cardiovasc Diabetol. 2025 Apr 16;24(1):163. doi: 10.1186/s12933-025-02729-1.
10
Association between non-highdensity lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and cardiovascular-kidney-metabolic syndrome: evidence from NHANES 2001-2018.非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值与心血管-肾脏-代谢综合征之间的关联：来自2001 - 2018年美国国家健康与营养检查调查（NHANES）的证据
Front Nutr. 2025 Feb 28;12:1548851. doi: 10.3389/fnut.2025.1548851. eCollection 2025.
Circ Res. 2018 May 11;122(10):1460-1478. doi: 10.1161/CIRCRESAHA.118.310082.
4
Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.抑制脑啡肽酶增强胰高血糖素样肽-1 受体信号：对心力衰竭患者的潜在影响。
Eur J Heart Fail. 2018 Jun;20(6):973-977. doi: 10.1002/ejhf.1185. Epub 2018 Mar 30.
5
Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications.药物预防和治疗心力衰竭的效果是否总是一致？他汀类药物悖论及其对理解抗糖尿病药物作用的启示。
Eur J Heart Fail. 2018 Jul;20(7):1100-1105. doi: 10.1002/ejhf.1183. Epub 2018 Mar 22.
6
Obesity: Pathophysiology and Management.肥胖：病理生理学与管理。
J Am Coll Cardiol. 2018 Jan 2;71(1):69-84. doi: 10.1016/j.jacc.2017.11.011.
7
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.恩格列净治疗2型糖尿病合并外周动脉疾病患者的心血管结局及安全性：EMPA-REG OUTCOME研究的亚组分析
Circulation. 2018 Jan 23;137(4):405-407. doi: 10.1161/CIRCULATIONAHA.117.032031. Epub 2017 Nov 13.
8
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.钠假说：SGLT2 抑制剂的心脏效应。
Cardiovasc Res. 2018 Jan 1;114(1):12-18. doi: 10.1093/cvr/cvx149.
9
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.每周一次艾塞那肽对2型糖尿病患者心血管结局的影响。
N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.
10
Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.恩格列净对2型糖尿病合并心血管疾病患者代谢特征的影响。
Circulation. 2017 Sep 5;136(10):969-972. doi: 10.1161/CIRCULATIONAHA.117.029166.